**Author details**

Anca Elena Sirbu\* , Aura Reghina, Carmen Barbu and Simona Fica

\*Address all correspondence to: ancaelenasirbu@yahoo.com

Carol Davila University of Medicine and Pharmacy, Endocrinology Department, Bucharest, Romania

### **References**


[14] Buchwald, H., et al*., Plasma lipids and cardiovascular risk: a POSCH report. Program on the Surgical Control of the Hyperlipidemias.* Atherosclerosis, 2001. 154(1): p. 221-7.

**Author details**

212 Treatment of Type 2 Diabetes

Anca Elena Sirbu\*

Romania

**References**

, Aura Reghina, Carmen Barbu and Simona Fica

Carol Davila University of Medicine and Pharmacy, Endocrinology Department, Bucharest,

[2] *National Diabetes Statistics Report, 2014 http://www.cdc.gov/diabetes/pubs/statsreport14/*

[3] Fox, C.S., et al., *Trends in the incidence of type 2 diabetes mellitus from the 1970s to the*

[4] Selvin, E., et al., *Trends in prevalence and control of diabetes in the United States,*

[5] Colditz, G.A., et al., *Weight gain as a risk factor for clinical diabetes mellitus in women.*

[6] Pasanisi, F., et al., *Benefits of sustained moderate weight loss in obesity.* Nutr Metab Car‐

[7] *UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group.* Metabolism, 1990. 39(9): p. 905-12.

[8] Look, A.R.G., *Eight-year weight losses with an intensive lifestyle intervention: the look*

[9] Look, A.R.G., et al., *Cardiovascular effects of intensive lifestyle intervention in type 2 diabe‐*

[11] Buchwald, H. and J.N. Buchwald, *Evolution of operative procedures for the management*

[12] Mason, E.E. and C. Ito, *Gastric bypass in obesity.* Surg Clin North Am, 1967. 47(6): p.

[13] Buchwald, H. and R.L. Varco, *Metabolic surgery*. Modern surgical monographs1978,

[10] Buchwald, H., *The Evolution of Metabolic/Bariatric Surgery.* Obes Surg, 2014.

*1990s: the Framingham Heart Study.* Circulation, 2006. 113(25): p. 2914-8.

*1988-1994 and 1999-2010*. Ann Intern Med, 2014. 160(8): p. 517-25.

*AHEAD study.* Obesity (Silver Spring), 2014. 22(1): p. 5-13.

*of morbid obesity 1950-2000.* Obes Surg, 2002. 12(5): p. 705-17.

\*Address all correspondence to: ancaelenasirbu@yahoo.com

[1] *Diabetes Atlas 6th Edition http://www.idf.org/diabetesatlas.*

*national-diabetes-report-web.pdfv*.

Ann Intern Med, 1995. 122(7): p. 481-6.

*tes.* N Engl J Med, 2013. 369(2): p. 145-54.

New York: Grune & Stratton. xii, 317 p.

1345-51.

diovasc Dis, 2001. 11(6): p. 401-6.


[45] Liou, A.P., et al., *Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity.* Sci Transl Med, 2013. 5(178): p. 178ra41.

[29] Little, T.J., M. Horowitz, and C. Feinle-Bisset, *Modulation by high-fat diets of gastrointes‐ tinal function and hormones associated with the regulation of energy intake: implications for*

[30] Browning, K.N., S.R. Fortna, and A. Hajnal, *Roux-en-Y gastric bypass reverses the effects of diet-induced obesity to inhibit the responsiveness of central vagal motoneurones.* J Physiol,

[31] Seravalle, G., et al., *Long-term sympathoinhibitory effects of surgically induced weight loss*

[32] Dirksen, C., et al., *Mechanisms of improved glycaemic control after Roux-en-Y gastric by‐*

[33] Vidal, J. and A. Jimenez, *Diabetes remission following metabolic surgery: is GLP-1 the cul‐*

[34] Holst, J.J., *The physiology of glucagon-like peptide 1.* Physiol Rev, 2007. 87(4): p. 1409-39.

[35] Dar, M.S., et al*., GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y*

[36] Jimenez, A., et al., *Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects.* Ann Surg, 2012. 256(6): p.

[37] Wilson-Perez, H.E., et al., *Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency.* Diabetes, 2013. 62(7): p. 2380-5.

[38] Rubino, F. and S.A. Amiel, *Is the gut the "sweet spot" for the treatment of diabetes?* Dia‐

[39] Patti, M.E. and A.B. Goldfine, *Hypoglycemia after gastric bypass: the dark side of GLP-1.*

[40] Staels, B. and V.A. Fonseca, *Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration.* Diabetes Care, 2009. 32 Suppl 2: p. S237-45.

[41] Gerhard, G.S., et al., *A role for fibroblast growth factor 19 and bile acids in diabetes remis‐*

[42] Ryan, K.K., et al., *FXR is a molecular target for the effects of vertical sleeve gastrectomy.*

[43] Aron-Wisnewsky, J., J. Dore, and K. Clement*, The importance of the gut microbiota after*

[44] Sweeney, T.E. and J.M. Morton, *The human gut microbiome: a review of the effect of obesi‐*

*sion after Roux-en-Y gastric bypass.* Diabetes Care, 2013. 36(7): p. 1859-64.

*bariatric surgery*. Nat Rev Gastroenterol Hepatol, 2012. 9(10): p. 590-8.

*ty and surgically induced weight loss.* JAMA Surg, 2013. 148(6): p. 563-9.

*the pathophysiology of obesity.* Am J Clin Nutr, 2007. 86(3): p. 531-41.

*in severe obese patients.* Hypertension, 2014. 64(2): p. 431-7.

*gastric bypass (RYGB)?* Obes Surg, 2012. 22(7): p. 1077-83.

*pass.* Diabetologia, 2012. 55(7): p. 1890-901.

*prit?* Curr Atheroscler Rep, 2013. 15(10): p. 357.

2013. 591(Pt 9): p. 2357-72.

214 Treatment of Type 2 Diabetes

1023-9.

betes, 2014. 63(7): p. 2225-8.

Gastroenterology, 2014. 146(3): p. 605-8.

Nature, 2014. 509(7499): p. 183-8.


[76] American Diabetes, A., *Standards of medical care in diabetes--2014.* Diabetes Care, 2014. 37 Suppl 1: p. S14-80.

[60] Dixon, J.B., et al., *Bariatric surgery: an IDF statement for obese Type 2 diabetes.* Diabet

[61] DeMaria, E.J., et al., *Results of 281 consecutive total laparoscopic Roux-en-Y gastric by‐ passes to treat morbid obesity.* Ann Surg, 2002. 235(5): p. 640-5; discussion 645-7.

[62] Hutter, M.M., et al., *First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass*. Ann Surg, 2011. 254(3): p. 410-20; discussion 420-2. [63] Encinosa, W.E., et al., *Recent improvements in bariatric surgery outcomes.* Med Care,

[64] DeMaria, E.J., D. Portenier, and L. Wolfe, *Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass.*

[65] Longitudinal Assessment of Bariatric Surgery, C., et al., *Perioperative safety in the lon‐ gitudinal assessment of bariatric surgery.* N Engl J Med, 2009. 361(5): p. 445-54.

[66] Sjostrom, L., et al., *Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric*

[67] Sjostrom, L., et al., *Bariatric surgery and long-term cardiovascular events.* JAMA, 2012.

[68] Still, C.D., et al., *Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study.* Lancet Diabetes Endocrinol, 2014. 2(1): p.

[69] Dixon, J.B., et al., *Predicting the glycemic response to gastric bypass surgery in patients*

[70] Ramos-Levi, A.M., et al., *Which criteria should be used to define type 2 diabetes remission*

[71] Robert, M., et al., *Predictive factors of type 2 diabetes remission 1 year after bariatric sur‐*

[72] Blackstone, R., et al., *Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status.* Surg Obes Relat Dis, 2012. 8(5): p.

[73] Lee, W.J., et al., *C-peptide predicts the remission of type 2 diabetes after bariatric surgery.*

[74] Aarts, E.O., et al., *Preoperative fasting plasma C-peptide level may help to predict diabetes*

[75] Ramos-Levi, A.M. and M.A. Rubio Herrera, *Metabolic surgery: quo vadis?* Endocrinol

*gery: impact of surgical techniques.* Obes Surg, 2013. 23(6): p. 770-5.

*outcome after gastric bypass surgery.* Obes Surg, 2013. 23(7): p. 867-73.

Med, 2011. 28(6): p. 628-42.

216 Treatment of Type 2 Diabetes

2009. 47(5): p. 531-5.

307(1): p. 56-65.

38-45.

548-55.

Surg Obes Relat Dis, 2007. 3(2): p. 134-40.

*surgery.* N Engl J Med, 2004. 351(26): p. 2683-93.

*with type 2 diabetes.* Diabetes Care, 2013. 36(1): p. 20-6.

*after bariatric surgery?* BMC Surg, 2013. 13: p. 8.

Obes Surg, 2012. 22(2): p. 293-8.

Nutr, 2014. 61(1): p. 35-46.

